Treatment of symptomatic patients with essential thrombocythemia: Effectiveness of anagrelide

American Journal of Hematology

Volumn 80, Issue 1, 2005, Pages 81-83

  Cacciola, Rossella R ^a,b   Cipolla, Antonio ^a   Di Francesco, Ernesto ^a   Giustolisi, Rosario ^a   Cacciola, Emma ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b Ospedale Ferrarotto   (Italy)

Author keywords

Anagrelide; Erythromelalgia; Essential thrombocythemia

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA 2 ANTIPLASMIN; ANAGRELIDE; ANTITHROMBOCYTIC AGENT; DIPYRIDAMOLE; INDOBUFEN; PLASMIN; PLASMINOGEN ACTIVATOR; PROTHROMBIN; THROMBOCYTE FACTOR 4; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIUM CELL; ERYTHROMELALGIA; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOSIS;

ADULT; AGED; BLOOD COAGULATION; FEMALE; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PLATELET FACTOR 4; QUINAZOLINES; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOSIS;

EID: 24344478510     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20399     Document Type: Article

References (9)

1. Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984;64(1):1-12.
2. van Genderen PJJ, Prins FJ, Michiels JJ, Schror K. Thromboxane-dependent platelet activation in vivo precedes arterial thrombosis in thrombocythemia: a rationale for the use of low-dose aspirin as an antithrombotic agent. Br J Haematol 1999;104:438-441.
3. Bellucci S, Ignatova E, Jaillet N, Boffa MC. Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, t-PA and vWF. Thromb Haemost 1993;70:736-742.
4. Spivak JL, Barosi G, Tognoni G, et al. Chronic myeloproliferative disorders. Hematology 2003;200-224.
5. Bajai MS, Birktoft JJ, Steer SA, Bajaj SP. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001;86:959-972.
6. Murphy S, Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol 1999;36(Suppl 2):9-13.
7. Laguna MS, Kornblihtt LI, Marta RF, Michiels JJ, Molinas FC. Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia. Clin Appl Thromb Hemost 2000;6:157-161.
8. Laguna MS, Kornblihtt LI, Marta RF, Molinas FC. Thromboxane B2 and platelet derived growth factor in essential thrombocythemia treated with anagrelide. Medicina (B Airs) 2000;60:448-452.
9. van Genderen PJ, Lucas IS, van Strik R, et al. Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation. Thromb Haemost 1996;76(3):333-338.